EDMA

This article is about a substituted amphetamine. For other uses, see EDMA (disambiguation).
EDMA
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17NO2
Molar mass207.273 g·mol−1
3D model (JSmol)
  • CC(Cc1ccc2c(c1)OCCO2)NC
  • InChI=1S/C12H17NO2/c1-9(13-2)7-10-3-4-11-12(8-10)15-6-5-14-11/h3-4,8-9,13H,5-7H2,1-2H3 checkY
  • Key:UJKWLAZYSLJTKA-UHFFFAOYSA-N checkY
  (verify)

3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the methamphetamine class.[1][2] It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring.[1][2] EDMA was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours.[1] According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects.[1] Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.[2]

  1. ^ a b c d e Shulgin A, Shulgin A (1991). Pihkal: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.
  2. ^ a b c McKenna DJ, Guan XM, Shulgin AT (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacology, Biochemistry, and Behavior. 38 (3): 505–512. doi:10.1016/0091-3057(91)90005-M. PMID 1829838. S2CID 2740262.